Rezolute, Inc.

Stocks

RZLT

US76200L3096

Market Closed - Nasdaq 00:00:00 25/09/2026 +04			5-day change	1st Jan Change
3.940 ^USD	-1.50%		-0.25%	+66.95%

09-09	Rezolute Says FDA Still Reviewing Ersodetug Data From Phase 3 Congenital Hyperinsulinism Study	MT
09-09	Rezolute Provides Update on FDA Review of Its Phase 3 Sunrize Study Results in Congenital Hyperinsulinism	CI

Transcript : Rezolute, Inc. - Special Call

Published on 12/11/2025 at 11:05 pm +04

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the sunRIZE Topline Data Conference Call. [Operator Instructions] Please note, this event is being recorded.

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Rezolute, Inc.

09-09	Rezolute Says FDA Still Reviewing Ersodetug Data From Phase 3 Congenital Hyperinsulinism Study	MT
09-09	Rezolute Provides Update on FDA Review of Its Phase 3 Sunrize Study Results in Congenital Hyperinsulinism	CI
08-25	Rezolute Shares to Show Strength Towards Upcoming Ersodetug Catalysts, Wedbush Says	MT
06-17	Rezolute, Inc. Highlights Results from Natural History Outcomes Studies and Its Ersodetug Clinical Program in Hyperinsulinism At Annual Meeting of the Endocrine Society	CI
06-03	Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating	MT
06-02	Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial	MT
06-02	Rezolute, Inc. Provides Positive Interim Data For Its Phase 3 UpLIFT Study Of Ersodetug In Tumor Hyperinsulinism	CI
06-02	Rezolute Says 6 Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial	MT
05-13	Rezolute, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-01	Rezolute Inc Announces Oral Presentation Of Results From Phase 3 Sunrize Study Of Ersodetug In Patients With Congenital Hyperinsulinism	CI
03-25	Wedbush Upgrades Rezolute to Outperform From Neutral, Raises Price Target to $5 From $2	MT
03-24	Rezolute Shares Rise After US FDA Encourages Data Submission for Congenital Hyperinsulinism Program	MT
03-24	Rezolute Inc Provides Update on Congenital Hyperinsulinism Program Following Fda Meeting	CI
03-24	Rezolute Says It Had Encouraging FDA Meeting on Congenital Hyperinsulinism Drug Despite Missed Endpoint	DJ
03-24	Rezolute Says US FDA Encourages Data Submission for Congenital Hyperinsulinism Program	MT

Chart Rezolute, Inc.

Duration

Period

RZLT: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

More financial data

Ratings

More Ratings

EPS Estimates

Revisions to estimates